Zacks: Brokerages Anticipate Atara Biotherapeutics Inc (ATRA) to Post -$1.18 EPS

Wall Street brokerages forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share of ($1.18) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.17) and the lowest is ($1.18). Atara Biotherapeutics posted earnings per share of ($1.02) in the same quarter last year, which would indicate a negative year over year growth rate of 15.7%. The company is scheduled to report its next quarterly earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.58) per share for the current financial year, with EPS estimates ranging from ($4.59) to ($4.58). For the next financial year, analysts forecast that the business will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks’ EPS calculations are an average based on a survey of research firms that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.17).

Several research analysts have recently commented on the company. BidaskClub downgraded Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 price objective on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $47.80.

In related news, CEO Isaac E. Ciechanover sold 7,800 shares of the business’s stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $38.00, for a total transaction of $296,400.00. Following the transaction, the chief executive officer now owns 812,613 shares in the company, valued at approximately $30,879,294. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joe Newell sold 10,000 shares of the business’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $35.78, for a total value of $357,800.00. Following the transaction, the insider now owns 41,858 shares in the company, valued at approximately $1,497,679.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,575 shares of company stock worth $3,633,158. Company insiders own 10.60% of the company’s stock.

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in Atara Biotherapeutics during the 1st quarter valued at about $107,000. Great West Life Assurance Co. Can increased its holdings in Atara Biotherapeutics by 100.1% during the 2nd quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 1,655 shares during the period. Bank of Montreal Can purchased a new position in Atara Biotherapeutics during the 2nd quarter valued at about $180,000. Principal Financial Group Inc. purchased a new position in Atara Biotherapeutics during the 1st quarter valued at about $214,000. Finally, Highland Private Wealth Management purchased a new position in Atara Biotherapeutics during the 2nd quarter valued at about $202,000.

ATRA opened at $36.42 on Friday. The stock has a market capitalization of $1.87 billion, a PE ratio of -9.11 and a beta of 2.54. Atara Biotherapeutics has a 12 month low of $12.65 and a 12 month high of $54.45.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Read More: How to Invest in Marijuana Stocks

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply